IP Library › Granted Patent US 12,194,096
Granted Patent B2
US 12,194,096 · App. 17/086,704 · Granted Jan 14, 2025

Composition and methods for preventing and treating African swine fever in wild and domestic swine

Inventor: Thomas A. Schultz (Oviedo, FL)
Assignee: STEVENS LAW GROUP
A61K39/42A61K35/20A61K45/06A61P31/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,194,096
App. No.
17/086,704
Granted
Jan 14, 2025
Kind
B2
Abstract

A composition for treatment of African Swine Fever in swine includes avian-sourced antibodies specific for an African Swine Fever Virus isolate. These antibodies are produced by avian animals immunized against the African Swine Fever Virus isolate and mixed with a protective/reactive matrix obtained from, isolated from, or derived from, non-hyperimmune colostrum.

Claims (9)

1. A composition for treatment of African Swine Fever in swine, the composition comprising

avian-sourced polyclonal antibodies specific for an African Swine Fever Virus isolate, wherein said polyclonal antibodies are produced by avian animals immunized against the African Swine Fever Virus isolate; and

a protective/reactive matrix obtained from, isolated from, or derived from, non-hyperimmune colostrum, wherein the composition is administered to an animal to prevent or treat an occurrence of African Swine Fever in the animal.

2. The composition of claim 1 , wherein the non-hyperimmune colostrum is at least part bovine derived.

3. The composition of claim 1 , further comprising at least one probiotic culture.

4. The composition of claim 1 , further comprising at least one prebiotic.

5. The composition of claim 1 , further comprising a mixture of electrolytes.

6. The composition of claim 1 , further comprising at least one growth factor.

7. The composition of claim 1 , further comprising at least one intestinotrophic growth factor.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2025
From: STEVENS LAW GROUP
To: MAMMAL LABS INC.
Reel/Frame 070655/0729 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 20, 2024
From: SINGER, KEVIN
To: STEVENS LAW GROUP
Reel/Frame 067467/0978 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2023
From: ANUBIS BIO CORP.
To: SINGER, KEVIN
Reel/Frame 064682/0936 →
COURT ORDER Recorded Aug 16, 2023
From: ANUBIS BIO CORP.
To: SINGER, KEVIN
Reel/Frame 064612/0583 →
LIEN Recorded May 22, 2023
From: ANUBIS BIO CORP.
To: STEVENS LAW GROUP
Reel/Frame 063720/0825 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2020
From: SCHULTZ, THOMAS A.
To: ANUBIS BIO CORPORATION
Reel/Frame 054241/0501 →
Continuity (2)
Provisional Application 62928647 · Oct 31, 2019
Related Publication 20210252148A1 · Aug 19, 2021
References Cited (11)
US 20050079244A1 · Giffard · 2005 [cited by examiner]
US 20170327564A1 · Starzl · 2017 [cited by applicant]
CN 110078819A · 2019 [cited by applicant]
Wu et al (Journal of Molecular Biology vol. 294, pp. 151-162) (Year: 1999). [cited by examiner]
MacCallum et al (J. Mol. Biol. vol. 262, pp. 732-745) (Year: 1996). [cited by examiner]
Skolnick et al (Trends in Biotechnology vol. 18, pp. 34-39) (Year: 2000). [cited by examiner]
Casset (Biochemical and Biophysical Research Communications vol. 307, pp. 198-205) (Year: 2003). [cited by examiner]
Vajdos et al (Journal of Molecular Biology vol. 320, pp. 415-428) (Year: 2002). [cited by examiner]
Zhang et al (Chinese Veterinary Science vol. 45 (8) pp. 821-825) (Year: 2015). [cited by examiner]
He, Y et al. Transgenic Soybean Production of Bioactive Human Epidermal Growth Factor EGF. PLoS One. Jun. 17, 2016. [cited by applicant]
Chen, X et al. Recombinant Newcastle disease virus expressing African swine fever virus protein 72 is safe and immunogenic in mice. Virologica Sinica. Apr. 2016. [cited by applicant]